{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:22:15Z","timestamp":1745986935424,"version":"3.40.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,29]]},"DOI":"10.7759\/cureus.83202","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T20:12:11Z","timestamp":1745957531000},"source":"Crossref","is-referenced-by-count":0,"title":["Double Trouble: A Case Report of Hydralazine-Induced Vasculitis and Lupus"],"prefix":"10.7759","author":[{"given":"Malika","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanda","family":"Aung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sravani","family":"Penumarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette JC","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, et al.. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013, 65:1-11. 10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/11588500-000000000-00000","article-title":"Drug-induced lupus erythematosus: incidence, management and prevention","volume":"34","author":"Chang C","year":"2011","unstructured":"Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011, 34:357-74. 10.2165\/11588500-000000000-00000","journal-title":"Drug Saf"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.289.6442.410","article-title":"The lupus syndrome induced by hydralazine: a common complication with low dose treatment","volume":"289","author":"Cameron HA","year":"1984","unstructured":"Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. Br Med J (Clin Res Ed). 1984, 289:410-2. 10.1136\/bmj.289.6442.410","journal-title":"Br Med J (Clin Res Ed)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198106020-00003","article-title":"Acetylator phenotype and lupus erythematosus","volume":"6","author":"Uetrecht JP","year":"1981","unstructured":"Uetrecht JP, Woosley RL. Acetylator phenotype and lupus erythematosus. Clin Pharmacokinet. 1981, 6:118-34. 10.2165\/00003088-198106020-00003","journal-title":"Clin Pharmacokinet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<405::AID-ANR22>3.0.CO;2-5","article-title":"Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies","volume":"43","author":"Choi HK","year":"2000","unstructured":"Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum. 2000, 43:405-13. 10.1002\/1529-0131(200002)43:2&lt;405::AID-ANR22&gt;3.0.CO;2-5","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-009-0168-y","article-title":"Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis","volume":"19","author":"Yokogawa N","year":"2009","unstructured":"Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009, 19:338-47. 10.1007\/s10165-009-0168-y","journal-title":"Mod Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000014","article-title":"Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis","volume":"26","author":"Pendergraft WF 3rd","year":"2014","unstructured":"Pendergraft WF 3rd, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol. 2014, 26:42-9. 10.1097\/BOR.0000000000000014","journal-title":"Curr Opin Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010050472","article-title":"Updates on the treatment of lupus nephritis","volume":"21","author":"Bomback AS","year":"2010","unstructured":"Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010, 21:2028-35. 10.1681\/ASN.2010050472","journal-title":"J Am Soc Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.01.005","article-title":"Hydralazine-associated vasculitis: overlapping features of drug-induced lupus and vasculitis","volume":"48","author":"Kumar B","year":"2018","unstructured":"Kumar B, Strouse J, Swee M, Lenert P, Suneja M. Hydralazine-associated vasculitis: overlapping features of drug-induced lupus and vasculitis. Semin Arthritis Rheum. 2018, 48:283-7. 10.1016\/j.semarthrit.2018.01.005","journal-title":"Semin Arthritis Rheum"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-015-0545-9","article-title":"Drug-induced vasculitis: new insights and a changing lineup of suspects","volume":"17","author":"Grau RG","year":"2015","unstructured":"Grau RG. Drug-induced vasculitis: new insights and a changing lineup of suspects. Curr Rheumatol Rep. 2015, 17:71. 10.1007\/s11926-015-0545-9","journal-title":"Curr Rheumatol Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-020-02378-w","article-title":"Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report","volume":"14","author":"Al-Abdouh A","year":"2020","unstructured":"Al-Abdouh A, Siyal AM, Seid H, Bekele A, Garcia P. Hydralazine-induced antineutrophil cytoplasmic antibody-associated vasculitis with pulmonary-renal syndrome: a case report. J Med Case Rep. 2020, 14:47. 10.1186\/s13256-020-02378-w","journal-title":"J Med Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-227161","article-title":"Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome","volume":"2018","author":"Aeddula NR","year":"2018","unstructured":"Aeddula NR, Pathireddy S, Ansari A, Juran PJ. Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. BMJ Case Rep. 2018, 2018:10.1136\/bcr-2018-227161","journal-title":"BMJ Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfm493","article-title":"Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study","volume":"22","author":"Lionaki S","year":"2007","unstructured":"Lionaki S, Hogan SL, Falk RJ, et al.. Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant. 2007, 22:3508-15. 10.1093\/ndt\/gfm493","journal-title":"Nephrol Dial Transplant"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4172\/2471-9544.100115","article-title":"Drug-induced lupus syndrome","volume":"2","author":"Tetikkurt C","year":"2016","unstructured":"Tetikkurt C. Drug-induced lupus syndrome. J Vasc. 2016, 2:1-5. 10.4172\/2471-9544.100115","journal-title":"J Vasc"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806023182209","article-title":"Drug-related lupus","volume":"318","author":"Hess E","year":"1988","unstructured":"Hess E. Drug-related lupus. N Engl J Med. 1988, 318:1460-2. 10.1056\/NEJM198806023182209","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates M","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, et al.. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016, 75:1583-94. 10.1136\/annrheumdis-2016-209133","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/352572-double-trouble-a-case-report-of-hydralazine-induced-vasculitis-and-lupus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T20:12:11Z","timestamp":1745957531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/352572-double-trouble-a-case-report-of-hydralazine-induced-vasculitis-and-lupus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.83202","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}